Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.31 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715131 | 1.00 | CACNA2D1 (0.35) | CACNA2D1TAAR1CTSBCTSSCTSK | |
| SCHEMBL5526174 | 0.90 | L3MBTL1 (0.35) | CACNA2D1CTSSCTSKCYSLTR2CYSLTR1 | |
| SCHEMBL4716947 | 0.90 | L3MBTL1 (0.35) | CACNA2D1CTSSCTSKCYSLTR2CYSLTR1 | |
| SCHEMBL5521342 | 0.88 | TAAR1 (0.38) | CACNA2D1TAAR1CTSBCTSSCTSK | |
| SCHEMBL4711021 | 0.88 | TAAR1 (0.38) | CACNA2D1TAAR1CTSBCTSSCTSK | |
| SCHEMBL4715133 | 0.83 | TAAR1 (0.38) | TAAR1CTSBCTSSCTSKRIPK1 | |
| SCHEMBL5518676 | 0.78 | RIPK1 (0.35) | TAAR1CTSBCTSSCTSKRIPK1 | |
| SCHEMBL4714957 | 0.77 | L3MBTL1 (0.35) | CTSSCTSKBACE1 | |
| SCHEMBL5524693 | 0.77 | L3MBTL1 (0.35) | CTSSCTSKBACE1 | |
| SCHEMBL14416512 | 0.76 | CACNA2D1 (0.67) | CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | PER2, CNR2, OPRD1 | CACNA2D1 13/4885TAAR1 462/4885CTSB 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.